Y
Yimofeng Biotechnology
Advanced CAR-T cell therapies for solid tumors
About Yimofeng Biotechnology
Yimofeng Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation Chimeric Antigen Receptor (CAR) T-cell immunotherapies for the treatment of cancer. The company is particularly concentrated on addressing the challenges associated with treating solid tumors.
The core of Yimofeng's research involves reprogramming a patient's own T-cells to recognize and attack cancer cells. A key area of their work includes developing strategies to overcome the immunosuppressive tumor microenvironment, which often limits the effectiveness of CAR-T therapies in solid tumors. One novel approach involves an inverted cytokine receptor (ICR) designed to block inhibitory signals like TGF-β within the tumor and convert them into stimulative signals for the CAR-T cells, enhancing their persistence and function.
The company has a pipeline of candidates, including treatments for metastatic colorectal cancer (mCRC) and prostate cancer. Its lead program, GCC19CART, has shown promising clinical activity in treating relapsed/refractory mCRC in trials conducted in both China and the United States, with the potential to be a first-in-class CAR-T product for this type of cancer. Yimofeng operates as an integrated international biotechnology firm with a proprietary CoupledCAR™ platform, designed to enhance the in-vivo expansion and efficacy of CAR-T cells against metastatic solid tumors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 18.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2022 | $28M | $110M | Guosheng Capital · SDIC Venture Capital | ↗ |
| SPINOUT✓Other financing | Jul 2020 | $0 | — | Fudan University · Shanghai Jiao Tong University | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yimofeng Biotechnology in the Suzhou Shi ecosystem
The Yimofeng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- GCGuosheng Capital
SDIC Venture Capital
Other known investors2 additional known investors
Fudan University
Shanghai Jiao Tong University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yimofeng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yimofeng Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









